Amedeo Smart

Free Medical Literature Service

 

Amedeo

Bacterial Infections and Mycoses
  Free Subscription

Articles published in
Lancet
    June 2024
  1. HYDE L
    Mobile screening for Ukraine's wartime tuberculosis epidemic.
    Lancet. 2024;403:2771.
    >> Share

  2. MCCANN N, Vicentine MP, Pollard AJ
    Towards paratyphoid control: the vital role of the challenge model.
    Lancet. 2024;403:2780-2781.
    >> Share

  3. CRENNER C
    Ulcers, stress, and the discovery of Helicobacter pylori.
    Lancet. 2024;403:2586-2587.
    >> Share

  4. WHITE NJ
    Death from diphtheria.
    Lancet. 2024;403:2590-2591.
    >> Share

  5. LIOU JM, Malfertheiner P, Smith SI, El-Omar EM, et al
    40 years after the discovery of Helicobacter pylori: towards elimination of H pylori for gastric cancer prevention.
    Lancet. 2024;403:2570-2572.
    >> Share

  6. ALMADI MA, Lu Y, Alali AA, Barkun AN, et al
    Peptic ulcer disease.
    Lancet. 2024 Jun 14:S0140-6736(24)00155-7. doi: 10.1016/S0140-6736(24)00155.
    >> Share

  7. MARIONI G, Franz L, Incognito A, Bitonti S, et al
    Bilateral simultaneous cochlear implant in an adult with anacusis due to bacterial meningitis.
    Lancet. 2024;403:2533.
    >> Share

  8. MOLINELLI E, Simonetti O
    Bimekizumab: dual inhibition as a promising tool in the management of hidradenitis suppurativa.
    Lancet. 2024;403:2457-2459.
    >> Share

  9. ASHINZE P, Mafua N, Obafemi E
    Nigeria rolls out novel meningitis vaccine.
    Lancet. 2024;403:2373.
    >> Share

    May 2024
  10. KIMBALL AB, Jemec GBE, Sayed CJ, Kirby JS, et al
    Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials.
    Lancet. 2024 May 22:S0140-6736(24)00101-6. doi: 10.1016/S0140-6736(24)00101.
    >> Share

  11. LEWNARD JA, Charani E, Gleason A, Hsu LY, et al
    Burden of bacterial antimicrobial resistance in low-income and middle-income countries avertible by existing interventions: an evidence review and modelling analysis.
    Lancet. 2024 May 20:S0140-6736(24)00862-6. doi: 10.1016/S0140-6736(24)00862.
    >> Share

  12. OKEKE IN, de Kraker MEA, Van Boeckel TP, Kumar CK, et al
    The scope of the antimicrobial resistance challenge.
    Lancet. 2024 May 20:S0140-6736(24)00876-6. doi: 10.1016/S0140-6736(24)00876.
    >> Share

  13. LAXMINARAYAN R, Impalli I, Rangarajan R, Cohn J, et al
    Expanding antibiotic, vaccine, and diagnostics development and access to tackle antimicrobial resistance.
    Lancet. 2024 May 20:S0140-6736(24)00878-X. doi: 10.1016/S0140-6736(24)00878.
    >> Share

  14. DE OLIVEIRA FRANCO A, Uberti Dos Santos V, von Ameln Lovison O, Zavascki AP, et al
    Invasive liver abscess syndrome with central nervous system involvement caused by hypermucoviscous Klebsiella pneumoniae: positive string test.
    Lancet. 2024;403:2257-2258.
    >> Share

    March 2024
  15. RAQIB R
    Bivalent conjugate vaccines for typhoid and paratyphoid fever.
    Lancet. 2024 Mar 28:S0140-6736(24)00461-6. doi: 10.1016/S0140-6736(24)00461.
    >> Share

  16. KULKARNI PS, Potey AV, Bharati S, Kunhihitlu A, et al
    The safety and immunogenicity of a bivalent conjugate vaccine against Salmonella enterica Typhi and Paratyphi A in healthy Indian adults: a phase 1, randomised, active-controlled, double-blind trial.
    Lancet. 2024 Mar 28:S0140-6736(24)00249-6. doi: 10.1016/S0140-6736(24)00249.
    >> Share

  17. BURKI T
    Pivotal tuberculosis vaccine trial begins.
    Lancet. 2024;403:1125.
    >> Share

  18. BHARGAVA A, Bhargava M, Pai M
    Tuberculosis: a biosocial problem that requires biosocial solutions.
    Lancet. 2024 Mar 20:S0140-6736(24)00489-6. doi: 10.1016/S0140-6736(24)00489.
    >> Share

  19. BURKI T
    The great cholera vaccine shortage.
    Lancet. 2024;403:891-892.
    >> Share

  20. SUBBARAMAN R, Fielding K
    Putting technology to the test in tuberculosis care.
    Lancet. 2024;403:878-879.
    >> Share

    February 2024
  21. KIMBALL AB, Ravichandran S
    Secukinumab treatment of hidradenitis suppurativa: questions remain - Authors' reply.
    Lancet. 2024;403:617-618.
    >> Share

  22. ENDO M, Kami M
    Secukinumab treatment of hidradenitis suppurativa: questions remain.
    Lancet. 2024;403:617.
    >> Share

  23. MAUL JT, Kolios AGA, Thomsen SF, Ring HC, et al
    Secukinumab treatment of hidradenitis suppurativa: questions remain.
    Lancet. 2024;403:616-617.
    >> Share

  24. PETERS RPH, Klausner JD, Mazzola L, Mdingi MM, et al
    Novel lateral flow assay for point-of-care detection of Neisseria gonorrhoeae infection in syndromic management settings: a cross-sectional performance evaluation.
    Lancet. 2024;403:657-664.
    >> Share

  25. PAI NP, Dillon JR
    A lateral flow assay for Neisseria gonorrhoeae: a step forward for an inexpensive biomarker-based diagnosis of N gonorrhoeae at the point of care?
    Lancet. 2024;403:594-595.
    >> Share

    January 2024
  26. WEI X, Hicks JP, Zhang Z, Haldane V, et al
    Effectiveness of a comprehensive package based on electronic medication monitors at improving treatment outcomes among tuberculosis patients in Tibet: a multicentre randomised controlled trial.
    Lancet. 2024 Jan 31:S0140-6736(23)02270-5. doi: 10.1016/S0140-6736(23)02270.
    >> Share

  27. PATEL PD, Liang Y, Meiring JE, Chasweka N, et al
    Efficacy of typhoid conjugate vaccine: final analysis of a 4-year, phase 3, randomised controlled trial in Malawian children.
    Lancet. 2024 Jan 25:S0140-6736(23)02031-7. doi: 10.1016/S0140-6736(23)02031.
    >> Share

  28. TADESSE BT, Cardona RSB, Marks F
    Long-term protection conferred by typhoid conjugate vaccines: a step towards typhoid elimination?
    Lancet. 2024 Jan 25:S0140-6736(23)02350-4. doi: 10.1016/S0140-6736(23)02350.
    >> Share

  29. CHICOINE N, Greenberg S
    Severe colonic distention and malnutrition in a 6-week-old infant: a case of Hirschsprung-associated enterocolitis.
    Lancet. 2024;403:282.
    >> Share

    November 2023
  30. SAMARASEKERA U
    Anurag and Madhavi Bhargava: enhancing TB prevention and care.
    Lancet. 2023;402:1740.
    >> Share

  31. WRENN K, Blomquist PB, Inzoungou-Massanga C, Olufon O, et al
    Surge of lower respiratory tract group A streptococcal infections in England in winter 2022: epidemiology and clinical profile.
    Lancet. 2023;402 Suppl 1:S93.
    >> Share

    October 2023
  32. MEMISH ZA, Blumberg L, Al-Maani AS, Baru R, et al
    Moving cholera vaccines ahead of the epidemic curve.
    Lancet. 2023 Oct 17:S0140-6736(23)02244-4. doi: 10.1016/S0140-6736(23)02244.
    >> Share

  33. BURKI T
    J&J patent decision to enable generic tuberculosis treatment.
    Lancet. 2023;402:1313.
    >> Share

    September 2023
  34. THE LANCET
    Tuberculosis: a different way of doing things.
    Lancet. 2023;402:937.
    >> Share

  35. REID M, Agbassi YJP, Arinaminpathy N, Bercasio A, et al
    Scientific advances and the end of tuberculosis: a report from the Lancet Commission on Tuberculosis.
    Lancet. 2023 Sep 13:S0140-6736(23)01379-X. doi: 10.1016/S0140-6736(23)01379.
    >> Share

  36. BEKO B, Furin J
    Beyond individual inclusion, investment in affected communities is needed to end tuberculosis.
    Lancet. 2023 Sep 13:S0140-6736(23)01892-5. doi: 10.1016/S0140-6736(23)01892.
    >> Share

    August 2023
  37. NELSON R
    Syphilis rates soar in the USA amid penicillin shortage.
    Lancet. 2023;402:515.
    >> Share

  38. BHARGAVA A, Bhargava M, Meher A, Benedetti A, et al
    Nutritional supplementation to prevent tuberculosis incidence in household contacts of patients with pulmonary tuberculosis in India (RATIONS): a field-based, open-label, cluster-randomised, controlled trial.
    Lancet. 2023 Aug 8:S0140-6736(23)01231-X. doi: 10.1016/S0140-6736(23)01231.
    >> Share

  39. SINHA P, Mehta S
    Food: the tuberculosis vaccine we already have.
    Lancet. 2023 Aug 8:S0140-6736(23)01321-1. doi: 10.1016/S0140-6736(23)01321.
    >> Share

    July 2023
  40. PEELING RW, Mabey D, Chen XS, Garcia PJ, et al
    Syphilis.
    Lancet. 2023;402:336-346.
    >> Share

    May 2023
  41. RICHARD M, Amiens P, Arregle F, Courand PY, et al
    Myocardial calcification: a rare consequence of streptococcal toxic shock.
    Lancet. 2023;401:1691.
    >> Share

    April 2023
  42. HAWKEY C
    Helicobacter pylori eradication and aspirin: a puzzle yet to be solved - Author's reply.
    Lancet. 2023;401:1266.
    >> Share

  43. GATTA L, Zullo A, Vaira D
    Helicobacter pylori eradication and aspirin: a puzzle yet to be solved.
    Lancet. 2023;401:1265-1266.
    >> Share

  44. REID M, Yamey G, Goosby E, Jamison D, et al
    Seizing opportunities to end TB: a call for ambition and optimism on World TB Day.
    Lancet. 2023;401:1153.
    >> Share

    March 2023
  45. KIRBY T
    Ruvandhi Nathavitharana: advancing TB diagnostics and advocacy.
    Lancet. 2023;401:990.
    >> Share

  46. KASAEVA T, Dias HM, Pai M
    Fast-tracking progress to End TB: high-level opportunities for investment and action.
    Lancet. 2023;401:975-978.
    >> Share

  47. KEECH C, Miller VE, Rizzardi B, Hoyle C, et al
    Immunogenicity and safety of BPZE1, an intranasal live attenuated pertussis vaccine, versus tetanus-diphtheria-acellular pertussis vaccine: a randomised, double-blind, phase 2b trial.
    Lancet. 2023;401:843-855.
    >> Share

  48. EDWARDS KM, Decker MD
    An alternative route to pertussis protection?
    Lancet. 2023;401:800-801.
    >> Share

  49. EGEBERG A, Thyssen JP
    The optimal biologic treatment target for hidradenitis suppurativa remains undiscovered.
    Lancet. 2023;401:708-710.
    >> Share

  50. KIMBALL AB, Jemec GBE, Alavi A, Reguiai Z, et al
    Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials.
    Lancet. 2023;401:747-761.
    >> Share

    February 2023
  51. BURKI T
    "Things have gone seriously wrong": global cholera surges.
    Lancet. 2023;401:633-634.
    >> Share

  52. AZIMINIA N, Soman B, Samoes J, Randhawa R, et al
    A diagnostic conundrum of a "ring of fire": a case of tuberculous perimyocarditis.
    Lancet. 2023;401:470-471.
    >> Share

    January 2023
  53. THOMPSON GR 3RD, Soriano A, Cornely OA, Kullberg BJ, et al
    Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial.
    Lancet. 2023;401:49-59.
    >> Share

    December 2022
  54. DANIELS JP
    Cholera surges in Haiti.
    Lancet. 2022;400:1913.
    >> Share

    November 2022
  55. GUINEA J
    Rezafungin and invasive candida infections: a new game changing antifungal?
    Lancet. 2022 Nov 25:S0140-6736(22)02371-6. doi: 10.1016/S0140-6736(22)02371.
    >> Share


  56. Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019.
    Lancet. 2022 Nov 18:S0140-6736(22)02185-7. doi: 10.1016/S0140-6736(22)02185.
    >> Share

  57. GOODALL RL, Meredith SK, Nunn AJ, Bayissa A, et al
    Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial.
    Lancet. 2022 Nov 7. pii: S0140-6736(22)02078.
    >> Share

  58. DHEDA K, Lange C
    A revolution in the management of multidrug-resistant tuberculosis.
    Lancet. 2022 Nov 7. pii: S0140-6736(22)02161.
    >> Share

  59. HAWKEY C, Avery A, Coupland CAC, Crooks C, et al
    Helicobacter pylori eradication for primary prevention of peptic ulcer bleeding in older patients prescribed aspirin in primary care (HEAT): a randomised, double-blind, placebo-controlled trial.
    Lancet. 2022;400:1597-1606.
    >> Share

  60. LANAS A, Santilli F
    Aspirin and Helicobacter pylori interaction.
    Lancet. 2022;400:1560-1561.
    >> Share

  61. JACKSON S, Kabir Z, Comiskey C
    Impact of universal tuberculosis vaccination cessation on the epidemiology of paediatric tuberculosis cases in Ireland from 2011 to 2021.
    Lancet. 2022;400 Suppl 1:S53.
    >> Share

  62. JACKSON S, Kabir Z, Comiskey C
    Divergence in pace of decline in tuberculosis rates among migrants versus non-migrants in Ireland from 2011 to 2020.
    Lancet. 2022;400 Suppl 1:S52.
    >> Share

    October 2022
  63. WIECH T, Reinhard L, Wulf S, Giuffrida AE, et al
    Bacterial infection possibly causing autoimmunity: Tropheryma whipplei and membranous nephropathy.
    Lancet. 2022 Oct 31. pii: S0140-6736(22)02039.
    >> Share

  64. MOK J, Lee M, Kim DK, Kim JS, et al
    9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial i
    Lancet. 2022;400:1522-1530.
    >> Share

  65. REUTER A, Furin J
    Celebrating choice in the care of people living with drug-resistant tuberculosis.
    Lancet. 2022;400:1489-1491.
    >> Share

    September 2022
  66. DEVI S
    War driving cholera in Syria.
    Lancet. 2022;400:986.
    >> Share

    August 2022
  67. MARKS GB, Horsburgh CR Jr, Fox GJ, Nguyen TA, et al
    Epidemiological approach to ending tuberculosis in high-burden countries.
    Lancet. 2022 Aug 4. pii: S0140-6736(22)01433.
    >> Share

    May 2022
  68. COUSINS S
    Eliminating cholera in Haiti.
    Lancet. 2022;399:1928-1929.
    >> Share

    April 2022
  69. PIETER Y, Grijsen ML
    Picturing health: the burden of leprosy in eastern Indonesia.
    Lancet. 2022;399:1588-1599.
    >> Share

  70. KANUNGO S, Azman AS, Ramamurthy T, Deen J, et al
    Cholera.
    Lancet. 2022;399:1429-1440.
    >> Share

    March 2022
  71. DHEDA K, Pinto L, Mutsvangwa J, Leung CC, et al
    Accelerate investment and action to find the missing patients with tuberculosis.
    Lancet. 2022 Mar 22. pii: S0140-6736(22)00535.
    >> Share

  72. YAKOVENKO V, Brauner R, Votinov E, Goldfarb Y, et al
    Infective endocarditis and thromboses due to antiphospholipid syndrome following acute Q fever.
    Lancet. 2022;399:1154.
    >> Share

  73. WATTS G
    Alberto Garcia-Basteiro: seeking better TB control in Mozambique.
    Lancet. 2022;399:1109.
    >> Share

    February 2022
  74. KUMAR A, Preston N, Phillips R
    Picturing health: Buruli ulcer in Ghana.
    Lancet. 2022;399:786-797.
    >> Share

  75. HEINING D, Plant AJ
    Steroid use in non-pneumococcal and non-Haemophilus bacterial meningitis.
    Lancet. 2022;399:717-718.
    >> Share

  76. VAN DE BEEK D, Brouwer MC, Koedel U, Wall EC, et al
    Steroid use in non-pneumococcal and non-Haemophilus bacterial meningitis - Authors' reply.
    Lancet. 2022;399:718.
    >> Share

  77. BEYRER C
    Archbishop Desmond Tutu and the universality of health and human rights.
    Lancet. 2022;399:503-504.
    >> Share

    January 2022
  78. VIGNESHWARAN J, Kumar MS, Raghavan V, Sundari S, et al
    Seizures and sideroblastic anaemia in a patient with multidrug-resistant tuberculosis.
    Lancet. 2022;399:393.
    >> Share


  79. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis.
    Lancet. 2022 Jan 18. pii: S0140-6736(21)02724.
    >> Share

  80. LAXMINARAYAN R
    The overlooked pandemic of antimicrobial resistance.
    Lancet. 2022 Jan 18. pii: S0140-6736(22)00087.
    >> Share

  81. MCCALL C
    Disrupted care in Papua New Guinea: the harms of COVID-19.
    Lancet. 2022;399:226-227.
    >> Share

    December 2021
  82. HOSSEINPOOR AR, Bergen N, Kirkby K, Schlotheuber A, et al
    Monitoring inequalities is a key part of the efforts to end AIDS, tuberculosis, and malaria.
    Lancet. 2021 Dec 8. pii: S0140-6736(21)02756.
    >> Share

    November 2021
  83. LANE R
    Pascale Ondoa: strengthening laboratory medicine in Africa.
    Lancet. 2021;398:1955.
    >> Share

    October 2021
  84. BUTLER-LAPORTE G, Halme A, Simard C
    Antibiotic treatment duration for bacteraemic pneumonia.
    Lancet. 2021;398:1485.
    >> Share

  85. DINH A
    Antibiotic treatment duration for bacteraemic pneumonia - Author's reply.
    Lancet. 2021;398:1485-1486.
    >> Share

  86. COUSSEMENT J, Dauby N
    Antibiotic treatment duration for bacteraemic pneumonia.
    Lancet. 2021;398:1484-1485.
    >> Share

  87. HEGDE A, Littlechild P, Taylor W
    Lumbar sediment sign seen in an unusual presentation of meningitis.
    Lancet. 2021;398:1436.
    >> Share

    September 2021
  88. LOW N, Hocking JS, van Bergen J
    The changing landscape of chlamydia control strategies.
    Lancet. 2021 Sep 22. pii: S0140-6736(21)02002.
    >> Share

  89. LANE R
    Gagandeep Kang: helping to shape a healthier India.
    Lancet. 2021;398:947.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016